Cargando…

Polyphenolic promiscuity, inflammation-coupled selectivity: Whether PAINs filters mask an antiviral asset

The Covid-19 pandemic has elicited much laboratory and clinical research attention on vaccines, mAbs, and certain small-molecule antivirals against SARS-CoV-2 infection. By contrast, there has been comparatively little attention on plant-derived compounds, especially those that are understood to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheridan, Rick, Spelman, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634583/
https://www.ncbi.nlm.nih.gov/pubmed/36339544
http://dx.doi.org/10.3389/fphar.2022.909945
_version_ 1784824528482861056
author Sheridan, Rick
Spelman, Kevin
author_facet Sheridan, Rick
Spelman, Kevin
author_sort Sheridan, Rick
collection PubMed
description The Covid-19 pandemic has elicited much laboratory and clinical research attention on vaccines, mAbs, and certain small-molecule antivirals against SARS-CoV-2 infection. By contrast, there has been comparatively little attention on plant-derived compounds, especially those that are understood to be safely ingested at common doses and are frequently consumed in the diet in herbs, spices, fruits and vegetables. Examining plant secondary metabolites, we review recent elucidations into the pharmacological activity of flavonoids and other polyphenolic compounds and also survey their putative frequent-hitter behavior. Polyphenols, like many drugs, are glucuronidated post-ingestion. In an inflammatory milieu such as infection, a reversion back to the active aglycone by the release of β-glucuronidase from neutrophils and macrophages allows cellular entry of the aglycone. In the context of viral infection, virions and intracellular virus particles may be exposed to promiscuous binding by the polyphenol aglycones resulting in viral inhibition. As the mechanism’s scope would apply to the diverse range of virus species that elicit inflammation in infected hosts, we highlight pre-clinical studies of polyphenol aglycones, such as luteolin, isoginkgetin, quercetin, quercetagetin, baicalein, curcumin, fisetin and hesperetin that reduce virion replication spanning multiple distinct virus genera. It is hoped that greater awareness of the potential spatial selectivity of polyphenolic activation to sites of pathogenic infection will spur renewed research and clinical attention for natural products antiviral assaying and trialing over a wide array of infectious viral diseases.
format Online
Article
Text
id pubmed-9634583
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96345832022-11-05 Polyphenolic promiscuity, inflammation-coupled selectivity: Whether PAINs filters mask an antiviral asset Sheridan, Rick Spelman, Kevin Front Pharmacol Pharmacology The Covid-19 pandemic has elicited much laboratory and clinical research attention on vaccines, mAbs, and certain small-molecule antivirals against SARS-CoV-2 infection. By contrast, there has been comparatively little attention on plant-derived compounds, especially those that are understood to be safely ingested at common doses and are frequently consumed in the diet in herbs, spices, fruits and vegetables. Examining plant secondary metabolites, we review recent elucidations into the pharmacological activity of flavonoids and other polyphenolic compounds and also survey their putative frequent-hitter behavior. Polyphenols, like many drugs, are glucuronidated post-ingestion. In an inflammatory milieu such as infection, a reversion back to the active aglycone by the release of β-glucuronidase from neutrophils and macrophages allows cellular entry of the aglycone. In the context of viral infection, virions and intracellular virus particles may be exposed to promiscuous binding by the polyphenol aglycones resulting in viral inhibition. As the mechanism’s scope would apply to the diverse range of virus species that elicit inflammation in infected hosts, we highlight pre-clinical studies of polyphenol aglycones, such as luteolin, isoginkgetin, quercetin, quercetagetin, baicalein, curcumin, fisetin and hesperetin that reduce virion replication spanning multiple distinct virus genera. It is hoped that greater awareness of the potential spatial selectivity of polyphenolic activation to sites of pathogenic infection will spur renewed research and clinical attention for natural products antiviral assaying and trialing over a wide array of infectious viral diseases. Frontiers Media S.A. 2022-10-21 /pmc/articles/PMC9634583/ /pubmed/36339544 http://dx.doi.org/10.3389/fphar.2022.909945 Text en Copyright © 2022 Sheridan and Spelman. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Sheridan, Rick
Spelman, Kevin
Polyphenolic promiscuity, inflammation-coupled selectivity: Whether PAINs filters mask an antiviral asset
title Polyphenolic promiscuity, inflammation-coupled selectivity: Whether PAINs filters mask an antiviral asset
title_full Polyphenolic promiscuity, inflammation-coupled selectivity: Whether PAINs filters mask an antiviral asset
title_fullStr Polyphenolic promiscuity, inflammation-coupled selectivity: Whether PAINs filters mask an antiviral asset
title_full_unstemmed Polyphenolic promiscuity, inflammation-coupled selectivity: Whether PAINs filters mask an antiviral asset
title_short Polyphenolic promiscuity, inflammation-coupled selectivity: Whether PAINs filters mask an antiviral asset
title_sort polyphenolic promiscuity, inflammation-coupled selectivity: whether pains filters mask an antiviral asset
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634583/
https://www.ncbi.nlm.nih.gov/pubmed/36339544
http://dx.doi.org/10.3389/fphar.2022.909945
work_keys_str_mv AT sheridanrick polyphenolicpromiscuityinflammationcoupledselectivitywhetherpainsfiltersmaskanantiviralasset
AT spelmankevin polyphenolicpromiscuityinflammationcoupledselectivitywhetherpainsfiltersmaskanantiviralasset